Biogen has decided to close down its digital health unit, formed just two years ago, as part of a major cost-reduction drive that has already claimed thousands of jobs.
Takeda has bolstered its neuroscience pipeline by licensing drug candidates from California biotech AcuraStem targeting PIKfyve, which is gathering attention as a drug tar
An alliance between German pharma group Boehringer Ingelheim and an NHS trust in the UK has been launched with the aim of reducing recurring heart attacks in people with d
Roche has bolstered its R&D pipeline in oncology and neuroscience with a pair of partnerships with Orionis Biosciences and PeptiDream, parting with upfront cash of $87
BeiGene confirmed today that Novartis has pulled out of a partnership on PD-1 inhibitor tislelizumab, two and half years after paying $650 million upfront for ex-China rig
AstraZeneca has made a sizeable play in applying artificial intelligence to drug discovery in its rare disease unit Alexion, partnering with Verge Genomics in a deal that
In an industry growing as quickly as cell therapy, keeping up with the demands of manufacturing and treatment is a challenge for the whole industry to tackle together, including stakeholder
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho